U.S. President Donald Trump’s push for lower U.S. drug prices has unexpectedly helped Astellas Pharma secure higher reimbursement pricing for its new eye medicine in Japan.
The Tokyo-based drugmaker, in a submission to Japanese officials, argued that domestic drug costs could influence U.S. pricing under Trump’s proposed most-favored nation scheme. Following this, Astellas won a reimbursement level for Izervay that was more generous than typical outcomes, Chief Executive Officer Naoki Okamura said in an interview.
“We leveraged this most favored nation dialog,” Okamura said. He believes Izervay got “relatively reasonable pricing” in Japan.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.